The four volunteer crew members spent more than 12 months inside NASA's first simulated Mars environment at Johnson Space Center in Houston. Photo via NASA

The crew of a NASA mission to Mars emerged from their craft after a yearlong voyage that never left Earth.

The four volunteer crew members spent more than 12 months inside NASA's first simulated Mars environment at Johnson Space Center in Houston, coming out of the artificial alien enviroment Saturday around 5 p.m.

Kelly Haston, Anca Selariu, Ross Brockwell and Nathan Jones entered the 3D-printed habitat on June 25, 2023, as the maiden crew of the space agency's Crew Health and Performance Exploration Analog project.

Haston, the mission commander, began with a simple, “Hello.”

“It’s actually just so wonderful to be able to say ‘hello’ to you all,” she said.

Jones, a physician and the mission medical officer, said their 378 days in confinement “went by quickly.”

The quartet lived and worked inside the space of 1,700 square feet (157 square meters) to simulate a mission to the red planet, the fourth from the sun and a frequent focus of discussion among scientists and sci-fi fans alike concerning a possible voyage taking humans beyond our moon.

The first CHAPEA crew focused on establishing possible conditions for future Mars operations through simulated spacewalks, dubbed “Marswalks,” as well as growing and harvesting vegetables to supplement their provisions and maintaining the habitat and their equipment.

They also worked through challenges a real Mars crew would be expected to experience including limited resources, isolation and delays in communication of up to 22 minutes with their home planet on the other side of the habitat's walls, NASA said.

Two additional CHAPEA missions are planned and crews will continue conducting simulated spacewalks and gathering data on factors related to physical and behavioral health and performance, NASA said.

Steve Koerner, deputy director of Johnson Space Center, said most of the first crew's experimentation focused on nutrition and how that affected their performance. The work was “crucial science as we prepare to send people on to the red planet,” he said.

“They've been separated from their families, placed on a carefully prescribed meal plan and undergone a lot of observation,” Koerner said.

“Mars is our goal,” he said, calling the project an important step in America's intent to be a leader in the global space exploration effort.

Emerging after a knock on the habitat's door by Kjell Lindgren, an astronaut and the deputy director of flight operations, the four volunteers spoke of the gratitude they had for each other and those who waited patiently outside, as well as lessons learned about a prospective manned mission to Mars and life on Earth.

Brockwell, the crew's flight engineer, said the mission showed him the importance of living sustainably for the benefit of everyone on Earth.

“I’m very grateful to have had this incredible opportunity to live for a year within the spirit of planetary adventure towards an exciting future, and I’m grateful for the chance to live the idea that we must utilise resources no faster than they can be replenished and produce waste no faster than they can be processed back into resources," Brockwell said.

“We cannot live, dream, create or explore on any significant timeframe if we don’t live these principles, but if we do, we can achieve and sustain amazing and inspiring things like exploring other worlds," he said.

Science officer Anca Selariu said she had been asked many times why there is a fixation on Mars.

“Why go to Mars? Because it’s possible,” she said. "Because space can unite and bring out the best in us. Because it’s one defining step that ‘Earthlings’ will take to light the way into the next centuries.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.